retatrutide phase FDA Approval Status 2026: Everything We Know So Far Retatrutide, a GIP, GLP-1 and

Patient and providers have linked other medications in this group, including Wegovy, Mounjaro, Rybelsus, Trulicity, and Zepbound, to issues like stomach paralysis

Rabbani and Thornalley, 2023, 2024)

There is no universal recommendation to supplement all patients receiving GLP-1-based therapies, but supplementation is appropriate and advisable in those with confirmed deficiency, borderline levels, or multiple risk factors for depletion

They will be offered to people based on factors beyond BMI, including genuine metabolic health risks, like sleep apnea or high blood pressure, the company said

Seventy percent of those that did not cover GLP-1s for obesity said they might add coverage if the cost was lower

This precision-wellness approach moves beyond one-size-fits-all protocols and supports safer, more effective treatment conversations